chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initially, I experienced only the expected side effects of the vaccine (e.g., slight discomfort at the location of the vaccine, slight achiness).  However, approx. 8 hours later, I began to experience significant pain in my arms and additional pain (not as severe) throughout my entire upper body.  The pain was so severe in the arms, that I was unable to lift them above my waist.  My neck was also quite stiff (it hurt to move it and I had a pounding headache.  Shortly thereafter I became nauseous, got freezing cold and began to shake uncontrollably.  The shaking continued on and off for about 45 minutes, but the movement from very cold to very hot, nausea, stiffness and headache continued throughout the night.  I was also unable to sleep.    The following day, I was still unable to move my arms without extreme discomfort and remained nauseous, fatigued and feverish through out the day.  By the second day after the shot, movement in my arms was restored, but the nausea and fatique continued, although to a lesser degree.  It is now the third day after the shot and the only remaining symptoms are slight achiness, nausea and soreness at the injection site (i.e., the expected symptoms).  I should note 3 facts:  (1) I had received the vaccine without incident approx. 5 1/2 years prior to this injection;  (2) I received the flu shot at the same time; (3) I had an allergy shot the prior Monday (could not find this listed in the pull down menu in no. 14)
Patient with known history of anaphylaxis to aspirin, carries epi pen.  1803 began feeling like hands were swelling.  NO SOB/tingling.  VSS.  127/71 P 85 RR 20, Sat 98%. 1804 Gave po Benadryl 25 mg, 1812 hands are red, swelling unable to remove ring.  Another 25 mg po Benadryl given.   Does not want to go to ED. Discussed with MD on site.  1830 able to remove ring, redness decreasing.  1845 Patients hands appear normal, no redness, swelling is gone.  Discussed with MD on site, agrees with release of pt, vitals remain stable Son is with her, has ride home, he will stay with her tonight, she has epi pen on hand and knows how to use it.  Instructed to take another 50 mg of Benadryl at night per MD, continue to monitor.  Call EMS for respiratory symptoms.
COVID-19  Chills  Body aches  Fatigue, unspecified type  Lyme disease  Nausea and vomiting, intractability of vomiting not specified, unspecified vomiting type  Acute nonintractable headache, unspecified headache type  Dyspnea on exertion  Acute midline low back pain without sciatica   Diarrhea, unspecified type  BMI 28.0-28.9,adult  Close exposure to COVID-19 virus  Fever, unspecified fever cause  Care Coordination Progress Note RN (Registered Nurse)    COVID 19 MAB Infusion Navigator Post Infusion Outreach #1   Infusion Date: 05/19/21   ED Course as of May 23 1036 Sun May 23, 2021 1025 EKG shows normal sinus rhythm rate 84 axis of 61.  There is no acute ST or T wave changes noted.  No signs of ST elevation.   [RS] 1032 Patient was given meclizine and Zofran and saline.  I reevaluated her.  She says she is feeling much better.  She is able to stand and walk without any difficulty.  I discussed keeping her for MRI as we cannot completely rule out stroke.  She verbalizes understanding of this.  She still wishes to go home.  She will get outpatient follow-up with her family doctor and return for worsening symptoms.  We will give her a prescription for meclizine.    Medication ? bamlanivimab/etesevimab ? casirivimab ? bamlanivimab
Over several days: On Fri. 09/18/15 had rash in both armpits. Symptoms subsided. On 09/19/15 at 11:00 AM rash returned. At 3 PM rash spread to back. By 4 PM was on neck and wrists. By 4:30 rash spread to left breast and to face. At 5 PM patient went to ER. Rash was extremely itchy. By 5:30 rash had spread to hips. Took one ALLEGRA at 5:30 PM, helped with itching. Rash subsided temporarily, but later spread to more of back and stomach. At 9 PM ER administered PO diphenhydramine 25 mg and prednisone 40 mg. MD examined her at 10:30 PM and prescribed more prednisone and antihistamine shot in left buttock. Discharged at 11 PM. On 09/20/15 minor rash still present on left side of body and both knees. In left leg joints began to ache. And had no energy. At 1 PM rash reappeared on face and neck and palms of hands. At 1 PM took one 25 mg diphenhydramine and one 10 mg loratadine and 3 prednisone 20 mg tabs, as prescribed. Symptoms lessened. New rash appeared on stomach and returned to face at 6:20 PM. At 9 PM rash appeared on soles of feet. At 11 PM reappeared on back, as well as stomach, chest, neck, armpits, hips and continued to spread until 1 AM. Took one of each previously mentioned meds. At 6 AM took one BENADRYL. Rash had disappeared from all parts of body except back of legs and buttocks. At 12 noon took two 20 mg of prednisone, one loratadine and one BENADRYL. At 3:30 saw MD for follow up. Patient is exhausted and concerned. Is shaking and reports low hand-eye coordination.
Body aches; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Body aches) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jan-2021, the patient experienced PAIN (Body aches). On 18-Jan-2021, PAIN (Body aches) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No treatment related information has been reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
citrus taste, a citrus taste in mouth, a citrus like lemon or lime, oranges or something; This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age and gender received BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot Number, Expiration date, NDC number and UPC number was unknown), via an unspecified route of administration on an unspecified date as dose number unknown, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date, patient experienced citrus taste, a citrus taste in mouth, a citrus like lemon or lime, oranges or something. Patient asked what to do. The outcome of the events was unknown.  Follow-up attempts are completed. No further information is expected, information on the lot/batch number cannot be obtained.
Flu shot given in Rt. deltoid, pt tensed up. Shot given on Tues. 10/18/2011 @ 10 AM Pt. already bruised above rt. elbow. Refused shot left arm. RTC on Thursday 10/20/2011 with bruising on Rt. deltoid. Denies NN, chills, HA or fever. Appt. made with MD 10/21/2011 @ 10 AM. Appt. kept.
Weakness; Fainted; Fever; Muscle Aches; Initial Report Received on 16-Sep-2021  A nurse in employee health in reported that a 21-year-old female (race and ethnicity not provided) received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization.  No medical history was reported.  The patient had no known allergies.   No concomitant medications were reported.  On 12-Aug-2021, the patient received the first dose of HEPLISAV-B (Lot # 934967, Expiration Date 01-Apr-2022, NDC # 4352800301) in the right deltoid.   On 12-Aug-2021, in the evening after having been vaccinated the HEPLISAV-B, the patient had a fever, weakness, muscle aches and "fainted." The patient regained consciousness and then went to sleep.  On 13-Aug-2021, the patient woke up in the morning still with a fever, but "felt better."  At 1000-1100, the patient's fever ended.    No additional information was provided.   Company comment: The company assessed the events as non-serious.; Sender's Comments: The company assessed the events as non-serious.
Was very sick for about a week.  Then was fine for the next week.  However then sick again for the next 3-4 weeks. Fatigue, bad cough, congestion.
Fever of 102 starting 3 and half hours after shot with chills, extreme muscle and joint pain. Diarrhea. All lasting 24 hours now fever is fluctuating between 99.8-101. No muscle pain or diarrhea just joint pain and low fever day two.
This is a spontaneous report from a contactable consumer (patient). A 71-year-old female received the second dose of BNT162B2 (Comirnaty, solution for injection, batch/lot# not reported, expiration date: unknown), via an unspecified route of administration, on an unspecified date, single dose, for COVID-19 immunization. The patient's medical history and concomitant medications not reported. The patient previously received the first dose of BNT162B2 (Comirnaty, solution for injection, batch/lot# not reported, expiration date: unknown), via an unspecified route of administration, on an unspecified date, single dose, for COVID-19 immunization and had a headache. On an unspecified date, patient had fatigue; with outcome of unknown. No follow-up attempts possible. Information about batch/lot number cannot be obtained.
I felt the worst kidney pain I've ever experienced in my left kidney. Nausea and suddenly heavy limbs brought me to the bathroom floor. I experienced tremors. I struggled to breathe/hyperventilated. Both of my hands seized up, with the thumbs curling inward and fingers in a strange position. I could not straighten them out for several minutes. Then the pain traveled down to my legs. This entire episode lasted about 45 minutes. Afterward, I felt dehydrated and fatigued, even though I never actually vomited.
Fever, nausea and vomiting, 24 hours, post vax. Resolved in 48 hours. Rx'd Motrin and fluids. May have been coincidental viral gastrointestinal.
extremity numbness    both hands and both feet   went to doctor  told to take motrin   didn't help still have same numbness now 05/20/2021
The patient presents with Potential stroke. Pt reports intermittent left central vision changes, onset "yesterday evening." Pt describes it as blurred vision that begins in the center of her vision and gradually expands. Pt adds that her family describes her as "foggy" states that her speech is not as clear, states onset was 2 days ago. PMHx significant for prior right sided CVA in 02/21, CAD, HTN, DM. Pt is not anticoagulated. Pt denies headache, dizziness, nausea, vomiting, altered gait, and all other symptoms.  The onset was "Yesterday evening".  63-year-old female with past medical history of coronary disease, hypertension, diabetes, carotid end arterectomy, depression, presents to ED with vision loss in the left-sided central vision loss that did not get better.   Patient has had complaints of cold symptoms and states that she was going to go and get a COVID test done but has not done so as of yet.  Furthermore states that she felt that her mentation was foggy and speech was not as clear either overnight.  Due to the vision loss she became extremely concerned and came to the hospital further evaluation.  Patient has a history of CVA on the right side back in February of 2021.  Patient is anticoagulated with Xarelto.  Upon arrival to the ED patient continues to have the vision loss but denies any other complaints besides the ones above.  COVID test was done and patient was positive for COVID-19.  Patient will be admitted for possible CVA and COVID-19 treatment.
CARDIAC ARREST; RESPIRATORY ARREST; ADVERSE DRUG REACTION; This spontaneous report was received from literature. This report concerned a 48 year adult male of unspecified race and ethnicity.  The objective of this study is to provide information and exposure case data collected during the course of providing patient-specific exposure management and poison information for entire year of 2021 by the Poison centers.  The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin was not reported, batch number: Unknown, expiry: Unknown) dose was not reported, 1 total, administered on an unspecified date for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported.  The Poison Data System (PDS) was a data warehouse for the PCs (poison controls). Poison centers place emphasis on exposure management, accurate data collection and coding, and responding to the continuing need for poison-related public and professional education. Poison center encounters involve either an exposed human or animal (exposure case) or a request for information with no person or animal exposed to any foreign body, viral, bacterial, venom, chemical agent or commercial product (Information request). All 55 PCs are accredited, and all submitted data to Poison Centers through 31-DEC-2021. Data from 703,086 information requests to PCs in 2021 were entered into PDS, including requests in optional reporting categories such as medical information (293,685), drug information (162,612), caller referred (69,618), poisons information (41,783) administrative (32,927), and prevention/safety/education (15,357). Total information requests to PCs decreased 37.0 percent from 2020 (1,116,568 requests) to 2021 (703,086 requests). Drug information requests increased 146 percent from 2020 (66,039) to 2021 (162,612) due to increase in requests to PCs about COVID-19 vaccines.  On an unspecified date, the patient had pre-hospital cardiac arrest, respiratory arrest and adverse drug reaction. On an unspecified date, the patient died from cardiac arrest, respiratory arrest and adverse drug reaction. An autopsy was performed on an unspecified date. The chronicity was acute exposure. The relative contribution to fatality was reported as contributory.  The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The authors emphasized that these data support the continued value of PC expertise and the need for specialized medical toxicology information to manage more serious exposures. This report was serious (Death).  .; Sender's Comments: V0: 20230215135-cardiac arrest, respiratory arrest, adverse drug reaction. The event has an unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event. Therefore, the WHO Causality is considered indeterminate. The company causality is considered unassessable.; Reported Cause(s) of Death: CARDIAC ARREST; RESPIRATORY ARREST; ADVERSE DRUG REACTION
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose01/10/21 2nd dose 02/27/21 Diagnosed covid positive:08/16/21 Symptom onset:08/14/21 Exposure:community Symptoms:fever, fatigue,loss of smell/taste, runny nose,HA
1st dose 2003, 2nd Aug2022. 3rd 07Apr2023; 19YO received adult dose; 19YO received adult dose; 1st dose 2003, 2nd Aug2022. 3rd 07Apr2023; This non-serious case was reported by a other health professional via call center representative and described the occurrence of overdose in a 19-year-old male patient who received HBV (Engerix B pediatric) (batch number P49X7, expiry date 07-DEC-2023) for prophylaxis.   Co-suspect products included HBV (Engerix B adult) for prophylaxis.   Previously administered products included Engerix B pediatric (received a pediatric dose of Engerix-B in 2003).   On 07-APR-2023, the patient received the 3rd dose of Engerix B pediatric. In AUG-2022, the patient received the 2nd dose of Engerix B adult. In AUG-2022, an unknown time after receiving Engerix B adult, the patient experienced overdose (Verbatim: 19YO received adult dose), adult product administered to child (Verbatim: 19YO received adult dose) and drug dose administration interval too long (Verbatim: 1st dose 2003, 2nd Aug2022. 3rd 07Apr2023). On 07-APR-2023, the patient experienced drug dose administration interval too long (Verbatim: 1st dose 2003, 2nd Aug2022. 3rd 07Apr2023). The outcome of the overdose, adult product administered to child, drug dose administration interval too long and drug dose administration interval too long were unknown.   Additional Information: GSK receipt date: 28-Apr-2023 The vaccine administration facility was the same as primary reporter. The reporter gave permission for follow-up, did not had email address to provide.  A pediatric patient received an adult dose of Engerix-B (2nd dose) and a pediatric dose of Engerix-B (3rd dose) later than the recommended interval, which led to overdose, adult product administered by child and drug dose administration interval too long.
Patient wanted to report his reaction after Moderna vaccine/reaction following vaccination; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Patient wanted to report his reaction after Moderna vaccine/reaction following vaccination) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Patient wanted to report his reaction after Moderna vaccine/reaction following vaccination). At the time of the report, VACCINATION COMPLICATION (Patient wanted to report his reaction after Moderna vaccine/reaction following vaccination) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment details were reported.  Company Comment: This case concerns a male subject of unknown age, with unknown medical history, who experienced the non-serious  unexpected event of Vaccination complication. The event occurred unknown number of days after a dose of mRNA 1273 VACCINE, dose number unknown. At the time of the report, outcome of the event was Unknown. Rechallenge is not applicable as no information regarding the dose number was given. The benefit-risk relationship of mRNA 1273 VACCINE is not affected by this report.; Sender's Comments: This case concerns a male subject of unknown age, with unknown medical history, who experienced the non-serious  unexpected event of Vaccination complication. The event occurred unknown number of days after a dose of mRNA 1273 VACCINE, dose number unknown. At the time of the report, outcome of the event was Unknown. Rechallenge is not applicable as no information regarding the dose number was given. The benefit-risk relationship of mRNA 1273 VACCINE is not affected by this report.
increased temp 102.4 F oral approx. 1 hr /p inject. Cyanotic face, hands & lower extremitites. Cold clamy feeling /w body shaking. No seizures. Rxn last approx. 15 min. No med intravention required.
This spontaneous report was received from a Registered Nurse, and refers to a female patient of unknown age. The patient's pertinent medical history, drug reactions and allergies were not reported. On an unknown date the patient was vaccinated with the 3rd dose series of RECOMBIVAX HB (dose, route of administration, anatomical location, lot # and expiration date were not provided) as a job requirement. Concomitant therapies were not reported. It was reported that the patient claimed she was not immune at the time of this report (hepatitis b surface antibody negative) It was uncertain if the patient was had titers drawn which showed negative immunity. No product quality issue was involved. Additional information has been requested.
WHOLE BODY ACHES; DRY COUGH; FEVER; HEADACHE; NAUSEA; This spontaneous report received from a consumer concerned a 62 year old male. The patient's weight was 205 pounds, and height was 69 inches. The patient's concurrent conditions included elevated cholesterol, arthritis, alcohol user, and non-smoker, and other pre-existing medical conditions included the patient had no known drug allergies. the patient did not have any history of drug abuse or illicit drug use.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: not reported) dose was not reported, administered on 07-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On APR-2021, the subject experienced nausea. On 07-APR-2021, the subject experienced fever. On 07-APR-2021, the subject experienced headache. On 08-APR-2021, the subject experienced whole body aches. On 08-APR-2021, the subject experienced dry cough. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever on 08-APR-2021, was recovering from whole body aches, dry cough, and headache, and the outcome of nausea was not reported. This report was non-serious.
tested positive for COVID after the first dose; tested positive for COVID after the first dose; This is a spontaneous report from a contactable Pharmacist reported for herself. A female patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number and expiry date unknown) via an unspecified route of administration on 22Dec2020 at single dose for Covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient informed that she had the COVID-19 vaccine exactly a week ago (22Dec2020). However, she was tested positive for COVID (Dec2020) after the first dose. The outcome of the events tested positive for COVID after the first dose was unknown. The patient asked if she can take the second dose.  Follow-up activities are possible, information on the batch number has been requested.; Sender's Comments: Based on the information currently available, a lack of efficacy with the suspected vaccine BNT162B2 in this patient cannot be completely excluded.  Further information like confirmative virus genome /nucleic acid detection needed for meaningful medical assessment.
Extreme pain in arm and shoulder.  Flu like symptoms X 24 hours.  Fever of 101.3, rash on right side of chest.
Headache, Fever, BODY ACHES & PAINS, CHILLS, LYMPHADENOPATHY Narrative:  Other Relevant History:
Had twice with shot/ Suspected vaccination failure; Had twice, not as bad 2nd time, they are nasty; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.     Additional Information: GSK receipt date: 09-FEB-2023 Reporter's comment: This case was reported by a patient via interactive digital media. The patient had received shot twice. The shot was not as bad second time. The reporter reported that shots were nasty. The reporter reported the insurance should pay. Additional Supportive Information: This case was considered as suspected vaccination failure as details regarding time to onset and laboratory test confirming shingles were unknown at the time of reporting. The follow-up could not be possible as no contact details were available.